Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204)

X
Trial Profile

An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Epacadostat (Primary) ; Pemigatinib (Primary) ; Retifanlimab (Primary) ; Tuparstobart; Verzistobart
  • Indications Endometrial cancer
  • Focus Therapeutic Use
  • Acronyms POD1UM-204
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 24 Oct 2023 Planned End Date changed from 22 Jun 2025 to 31 May 2026.
    • 24 Oct 2023 Planned primary completion date changed from 25 Aug 2023 to 30 Apr 2025.
    • 09 Feb 2023 This trial has been Discontinued in Germany (Date of the global end of the trial: 23-Jan-2023), according to the European Clinical Trials Database record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top